As filed with the Securities and Exchange Commission on February 28, 2024
Registration No. 333-
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S‑8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

RXSIGHT, INC.

(Exact name of registrant as specified in its charter)

Delaware		94-3268801
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

 

100 Columbia

Aliso Viejo, CA 92656

(949) 521-7830

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

2021 Equity Incentive Plan

(Full title of the plan)

 

Ron Kurtz, M.D.

President and Chief Executive Officer

RxSight, Inc.

100 Columbia

Aliso Viejo, CA 92656

(949) 521-7830

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Martin J. Waters Robert L. Wernli, Jr. Wilson Sonsini Goodrich & Rosati, P.C. 12235 El Camino Real San Diego, CA 92130 (858) 350-2300		Shelley Thunen Chief Financial Officer RxSight, Inc. 100 Columbia Aliso Viejo, CA 92656 (949) 521-7830

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☒		Accelerated filer	☐
Non-accelerated filer	☐		Smaller reporting company	☐
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐

 

---

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

This Registration Statement on Form S-8 (the “Registration Statement”) is filed by RxSight, Inc. (the “Registrant”) for the purpose of registering 1,445,580 additional shares of common stock of the Registrant that may be issued pursuant to the RxSight, Inc. 2021 Equity Incentive Plan.

In accordance with General Instruction E to Form S-8, the contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on July 30, 2021 (File No. 333-258292), Form S-8 filed by the Registrant with the SEC on March 8, 2022 (File No. 333-263374) and Form S-8 filed by the Registrant with the SEC on March 6, 2023 (File No. 333-270301) are incorporated by reference into this Registration Statement.

 

PART II

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

 

 

---

Item 8. Exhibits.

 

Exhibit		Incorporated by Reference
Number	Description	Form	File No.	Exhibit	Filing Date
4.1	Specimen common stock certificate of the Registrant	S-1/A	333-257790	4.2	July 26, 2021
4.2	2021 Equity Incentive Plan, and form agreements thereunder	10-Q	001-40690	10.2	November 10, 2021
5.1*	Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation
23.1*	Consent of Independent Registered Public Accounting Firm
23.2*	Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)
24.1*	Power of Attorney (contained on signature page hereto)
107*	Filing Fee Table
*	Filed herewith.

 

 

 

---

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Aliso Viejo, State of California, on February 28, 2024.

 

RXSIGHT, INC.
By:		/s/ Ron Kurtz, M.D.
		Ron Kurtz, M.D.
		President and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Shelley Thunen as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in their name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title				Date
/s/ Ron Kurtz, M.D.		President, Chief Executive Officer and Director (Principal Executive Officer)			February 28, 2024
Ron Kurtz, M.D.
/s/ Shelley Thunen		Chief Financial Officer (Principal Financial and Accounting Officer)			February 28, 2024
Shelley Thunen
/s/ J. Andy Corley		Chair of the Board			February 28, 2024
J. Andy Corley
/s/ William J. Link, Ph.D.		Director			February 28, 2024
William J. Link, Ph.D.
/s/ Juliet Tammenoms Bakker		Director			February 28, 2024
Juliet Tammenoms Bakker
/s/ Julie Andrews		Director			February 28, 2024
Julie Andrews
/s/ Robert Palmisano		Director			February 28, 2024
Robert Palmisano
/s/ Robert Warner		Director			February 28, 2024
Robert Warner
/s/ Shweta Singh Maniar		Director			February 28, 2024
Shweta Singh Maniar
/s/ Tamara R. Fountain, M.D.		Director			February 28, 2024
Tamara R. Fountain, M.D.

 

---

Exhibit 5.1

	Wilson Sonsini Goodrich & Rosati Professional Corporation 12235 El Camino Real San Diego, California 92130 o: 858-350-2300 f: 858-350-2399

February 28, 2024

 

RxSight, Inc.

100 Columbia

Aliso Viejo, California 92656

Re:	Registration Statement on Form S-8

Ladies and Gentlemen:

 

We have examined the Registration Statement on Form S-8 (the “Registration Statement”) to be filed by RxSight, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission on or about the date hereof, in connection with the registration under the Securities Act of 1933, as amended, of 1,445,580 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) reserved for future issuance under the Company’s 2021 Equity Incentive Plan (the “2021 Plan”). As the Company’s legal counsel, we have reviewed the actions proposed to be taken by the Company in connection with the issuance and sale of the Shares to be issued under the 2021 Plan.

It is our opinion that the Shares, when issued and sold in the manner referred to in the 2021 Plan and pursuant to the agreements that accompany the 2021 Plan, will be legally and validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement, and further consent to the use of our name wherever appearing in the Registration Statement and any amendments thereto.

Very truly yours,

/s/ Wilson Sonsini Goodrich & Rosati

WILSON SONSINI GOODRICH & ROSATI,

Professional Corporation

 

 

---

 

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the RxSight, Inc. 2021 Equity Incentive Plan of RxSight, Inc. of our reports dated February 28, 2024, with respect to the consolidated financial statements of RxSight, Inc. and the effectiveness of internal control over financial reporting of RxSight, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Irvine, California

February 28, 2024

 

---

																						Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
RxSight, Inc.
(Exact name of Registrant as Specified in its Charter)
Table 1 – Newly Registered Securities
Security Type		Security Class Title		Fee Calculation on Rule		Amount Registered (1)				Proposed Maximum Offering Price Per Share				Maximum Aggregate Offering Price				Fee rate				Amount of Registration Fee
Equity		Common Stock, $0.001 par value per share, reserved for issuance pursuant to the 2021 Equity Incentive Plan		457(c) and 457(h)			1,445,580		(2)	$	55.47		(3)	$	80,186,322.60				0.00014760			$	11,835.50
Total Offering Amounts							1,445,580							$	80,186,322.60							$	11,835.50
Total Fee Offsets																							—
Net Fee Due																						$	11,835.50

---